Novel artificial neural network for early detection of prostate cancer

Journal of Clinical Oncology

Volumn 20, Issue 4, 2002, Pages 921-929

  Djavan, Bob ^a   Remzi, Mesut ^a   Zlotta, Alexandre ^a   Seitz, Christian ^a   Snow, Peter ^a   Marberger, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL NEURAL NETWORK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATIENT COUNSELING; PATIENT REFERRAL; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL ANALYSIS; TISSUE DISTRIBUTION;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIOPSY; DECISION MAKING; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEURAL NETWORKS (COMPUTER); PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0037083655     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.4.921     Document Type: Article

References (35)

1. The clinical usefulness of prostate specific antigen: Update 1994
2. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
3. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
4. The clinical usefulness of percent free prostate-specific antigen
5. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system
6. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
7. Prostate-specific antigen density
8. Prostate-specific antigen velocity and repeated measures of prostate-specific antigen
9. Age-specific reference ranges for serum prostate-specific antigen
10. Prostate specific antigen density of the transition zone for early detection of prostate cancer
11. Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction
12. 1-antichymotrypsin before diagnosis of prostate cancer
13. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
14. Longitudinal screening for prostate cancer with prostate-specific antigen
15. PSAPSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL
16. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination
17. Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men
18. Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: Clinical and pathological features of detected cancer
19. Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen
20. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate
21. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies
22. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach
23. Percent free prostate-specific antigen: The next frontier in prostate-specific antigen testing
24. 1-antichymotrypsin as an indicator of prostate cancer
25. Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen
26. Clinical evaluation of two free PSA assays in combination with different total PSA assays
27. Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint scintiscans
28. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network
29. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL
30. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy
31. Artificial neural network analysis (ANNA) of prostatic transrectal ultrasound
32. Artificial neural networks in the diagnosis and prognosis of prostate cancer: A pilot study